In a controlled double blind study the therapeutic efficacy and tolerability of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy]
acetic acid (
acemetacin, TV 1322, Rantudil¿) and
tolmetin were compared in 40 patients suffering from acute and subacute painful
irritant conditions in the spinal area and joints. The maximal duration of the study was 20 days. In the case of acemetcin the daily dose was 90 mg and in the case of
tolmetin it was 600 mg. The clinical symptoms kinesalgia,
pain caused by pressure, and functional impairment were significantly improved by both
acemetacin and
tolmetin. A comparison of the two
therapy groups did not reveal any difference. Also a statistical comparison of the evaluations of the therapeutic efficacy by the physician did not reveal any significant difference, although the assessment "very good" occurred twice as frequently in the
acemetacin group (13 out of 20) as in the
tolmetin group (6 out of 20). In only one patient treated with
tolmetin undesired
drug reactions occurred. These resulted in discontinuation of the
therapy. No side effects occurred in the
acemetacin group.
Acemetacin, which in experimental animal investigations not only showed an antiinflammatory but also an
analgesic effect, is according to the results of our study also suitable for the
therapy of symptoms in which the
analgesic efficacy of a
drug decisively influences the therapeutic success.